Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

metformin

1000 mg to 2000 mg per day

DRUG

linagliptin

5 mg daily

DRUG

metformin placebo

0 to 2 tablets daily

DRUG

metformin placebo

4 tablets daily

Trial Locations (82)

Unknown

1218.83.11002 Boehringer Ingelheim Investigational Site, Phoenix

1218.83.11036 Boehringer Ingelheim Investigational Site, Little Rock

1218.83.11011 Boehringer Ingelheim Investigational Site, Chino

1218.83.11001 Boehringer Ingelheim Investigational Site, Huntington Beach

1218.83.11019 Boehringer Ingelheim Investigational Site, Huntington Park

1218.83.11015 Boehringer Ingelheim Investigational Site, Lomita

1218.83.11023 Boehringer Ingelheim Investigational Site, Norwalk

1218.83.11014 Boehringer Ingelheim Investigational Site, Roseville

1218.83.11031 Boehringer Ingelheim Investigational Site, San Diego

1218.83.11022 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1218.83.11025 Boehringer Ingelheim Investigational Site, Orlando

1218.83.11033 Boehringer Ingelheim Investigational Site, Sanford

1218.83.11029 Boehringer Ingelheim Investigational Site, Oakwood

1218.83.11026 Boehringer Ingelheim Investigational Site, Owensboro

1218.83.11008 Boehringer Ingelheim Investigational Site, Elkton

1218.83.11027 Boehringer Ingelheim Investigational Site, Freemont

1218.83.11005 Boehringer Ingelheim Investigational Site, Edison

1218.83.11013 Boehringer Ingelheim Investigational Site, Jacksonville

1218.83.11028 Boehringer Ingelheim Investigational Site, Salisbury

1218.83.11009 Boehringer Ingelheim Investigational Site, Shelby

1218.83.11003 Boehringer Ingelheim Investigational Site, Franklin

1218.83.11024 Boehringer Ingelheim Investigational Site, Gallipolis

1218.83.11018 Boehringer Ingelheim Investigational Site, Columbia

1218.83.11004 Boehringer Ingelheim Investigational Site, Bristol

1218.83.11017 Boehringer Ingelheim Investigational Site, Chattanooga

1218.83.11032 Boehringer Ingelheim Investigational Site, Grand Prairie

1218.83.11030 Boehringer Ingelheim Investigational Site, Houston

1218.83.11034 Boehringer Ingelheim Investigational Site, San Antonio

1218.83.11021 Boehringer Ingelheim Investigational Site, Tomball

1218.83.12011 Boehringer Ingelheim Investigational Site, Calgary

1218.83.12007 Boehringer Ingelheim Investigational Site, Edmonton

1218.83.12001 Boehringer Ingelheim Investigational Site, Red Deer

1218.83.12002 Boehringer Ingelheim Investigational Site, Paradise

1218.83.12009 Boehringer Ingelheim Investigational Site, St. John's

1218.83.12010 Boehringer Ingelheim Investigational Site, Greater Sudbury

1218.83.12005 Boehringer Ingelheim Investigational Site, Kitchener

1218.83.12006 Boehringer Ingelheim Investigational Site, London

1218.83.12003 Boehringer Ingelheim Investigational Site, Smiths Falls

1218.83.12012 Boehringer Ingelheim Investigational Site, Winnipeg

1218.83.91003 Boehringer Ingelheim Investigational Site, Bangalore

1218.83.91005 Boehringer Ingelheim Investigational Site, Chennai

1218.83.91001 Boehringer Ingelheim Investigational Site, Mumbai

1218.83.97004 Boehringer Ingelheim Investigational Site, Haifa

1218.83.97005 Boehringer Ingelheim Investigational Site, Haifa

1218.83.97007 Boehringer Ingelheim Investigational Site, Holon

1218.83.60001 Boehringer Ingelheim Investigational Site, Kelantan

1218.83.60002 Boehringer Ingelheim Investigational Site, Perak

1218.83.60003 Boehringer Ingelheim Investigational Site, Selangor, Malaysia

1218.83.52004 Boehringer Ingelheim Investigational Site, Cuautla

1218.83.52001 Boehringer Ingelheim Investigational Site, Guadalajara

1218.83.52002 Boehringer Ingelheim Investigational Site, Guadalajara

1218.83.52005 Boehringer Ingelheim Investigational Site, Mérida

1218.83.52003 Boehringer Ingelheim Investigational Site, Tampico

1218.83.63001 Boehringer Ingelheim Investigational Site, Cebu

1218.83.63007 Boehringer Ingelheim Investigational Site, Cebu City

1218.83.63003 Boehringer Ingelheim Investigational Site, Iloilo City

1218.83.63008 Boehringer Ingelheim Investigational Site, Iloilo City

1218.83.63002 Boehringer Ingelheim Investigational Site, Marikina City

1218.83.63006 Boehringer Ingelheim Investigational Site, Marikina City

1218.83.63004 Boehringer Ingelheim Investigational Site, Quezon

1218.83.11037 Boehringer Ingelheim Investigational Site, San Juan

1218.83.07001 Boehringer Ingelheim Investigational Site, Kazan'

1218.83.07002 Boehringer Ingelheim Investigational Site, Petrozavodsk

1218.83.07003 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.83.07007 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.83.07004 Boehringer Ingelheim Investigational Site, Samara

1218.83.07006 Boehringer Ingelheim Investigational Site, Smolensk

1218.83.07005 Boehringer Ingelheim Investigational Site, Yaroslavl

1218.83.94004 Boehringer Ingelheim Investigational Site, Dehiwala

1218.83.94002 Boehringer Ingelheim Investigational Site, Galle, Sri Lanka

1218.83.94003 Boehringer Ingelheim Investigational Site, Kandy

1218.83.94001 Boehringer Ingelheim Investigational Site, Ragama

1218.83.66002 Boehringer Ingelheim Investigational Site, Bangkok

1218.83.66003 Boehringer Ingelheim Investigational Site, Bangkok

1218.83.66001 Boehringer Ingelheim Investigational Site, Muang, Khonkaen

1218.83.38007 Boehringer Ingelheim Investigational Site, Dnipro

1218.83.38001 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk

1218.83.38006 Boehringer Ingelheim Investigational Site, Kharkiv

1218.83.38004 Boehringer Ingelheim Investigational Site, Odesa

1218.83.38008 Boehringer Ingelheim Investigational Site, Vinnitsa

1218.83.38003 Boehringer Ingelheim Investigational Site, Vinnytsia

1218.83.38005 Boehringer Ingelheim Investigational Site, Vinnytsia

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY